High Diagnostic Performance of Short Magnetic Resonance Imaging Protocols for Prostate Cancer Detection in Biopsy-naive Men: The Next Step in Magnetic Resonance Imaging Accessibility by van der Leest, M. et al.
E U RO P E AN URO L OGY 76 ( 2 019 ) 574 – 5 8 1
avai lable at www.sciencedirect .com
journal homepage: www.europeanurology.comPlatinum Priority – Prostate Cancer – Editor’s Choice
Editorial by Jochen Walz on pp. 582–583 of this issue
High Diagnostic Performance of Short Magnetic Resonance
Imaging Protocols for Prostate Cancer Detection in Biopsy-naïve
Men: The Next Step in Magnetic Resonance Imaging AccessibilityMarloes van der Leest a,y,*, Bas Israe¨l a,b,y, Erik Bastiaan Cornel c, Patrik Za´mecnik a, Ivo G. Schoots d,
Hans van der Lelij e, Anwar R. Padhani f, Maroeska Rovers g, Inge van Oort b, Michiel Sedelaar b,
Christina Hulsbergen-van de Kaa h, Gerjon Hannink g, Jeroen Veltman i,z, Jelle Barentsz a,z
aDepartment of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands; bDepartment of Urology, Radboud
University Medical Center, Nijmegen, The Netherlands; cDepartment of Urology, Ziekenhuis Groep Twente, Almelo-Hengelo, The Netherlands; dDepartment
of Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands; eDepartment of Radiology and Nuclear Medicine,
Maasstad Hospital, Rotterdam, The Netherlands; f Paul Strickland Scanner Centre, Mount Vernon Cancer Centre, Northwood, UK; gDepartment of Operating
Rooms, Radboud University Medical Center, Nijmegen, The Netherlands; h Laboratory Pathology Oost-Nederland, Hengelo, The Netherlands; iDepartment of
Radiology, Ziekenhuis Groep Twente, Almelo-Hengelo, The NetherlandsArticle info
Article history:
Accepted May 17, 2019
Associate Editor:
James Catto
Keywords:
Abbreviated prostate magnetic
resonance imaging protocols
Biparametric magnetic
resonance imaging
Diagnostic imaging
Dynamic contrast-enhanced
imaging
Prostate cancer
Prostate Imaging Reporting and
Data System
Abstract
Background: Tomakemagnetic resonance imaging (MRI)more accessible tomen at risk
of high-grade prostate cancer (PCa), there is a need for quicker, simpler, and less costly
MRI protocols.
Objective: To compare the diagnostic performance ofmonoplanar (“fast” biparametricMRI
[bp-MRI]) and triplanar noncontrast bp-MRI with that of the current contrast-enhanced
multiparametric MRI (mp-MRI) in the detection of high-grade PCa in biopsy-naïve men.
Design, setting, and participants: A prospective, multireader, head-to-head study in-
cluded 626 biopsy-naïve men, between February 2015 and February 2018.
Intervention: Men underwent prebiopsy contrast-enhanced mp-MRI. Prior to biopsy,
two blinded expert readers subsequently assessed “fast” bp-MRI, bp-MRI, and mp-MRI.
Thereafter, systematic transrectal ultrasound-guided biopsies (SBs) were performed.
Menwith suspicious mp-MRI (Prostate Imaging Reporting and Data System 3–5 lesions)
also underwent MR-in-bore biopsy (MRGB).
Outcome measurements and statistical analysis: Primary outcome was the diagnostic
performance of each protocol for the detection of high-grade PCa. Secondary outcomes
included the difference in biopsy avoidance, detection of low-grade PCa, acquisition
times, decision curve analyses, inter-reader agreement, and direct costs. Results from
combined MRGB and SB were used as the reference standard. High-grade PCa was
deﬁned as grade 2.
Results and limitations: Sensitivity for high-grade PCa for all protocols was 95% (180/
190; 95% conﬁdence interval [CI]: 91–97%). Speciﬁcity was 65% (285/436; 95% CI: 61–y Marloes van der Leest and Bas Israël are co-ﬁrst authors.
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70%) for “fast” bp-MRI and 69% (299/436; 95% CI: 64–73%) for bp-MRI and mp-MRI.
With fast bp-MRI, 0.96% (6/626) more low-grade PCa was detected. Biopsy could be
avoided in 47% for the fast bp-MRI and in 49% for the bp-MRI and mp-MRI protocols.
Fast bp-MRI and bp-MRI can be performed in 8 and 13 min, respectively, instead of
16 min at lower direct costs. Inter-reader agreement was 90% for fast bp-MRI protocol
and 93% for bp-MRI protocol. Amain limitation is the generalizability of these results in
less experienced centers.
Conclusions: Short MRI protocols can improve prostate MRI accessibility at a lower
direct cost. For fast bp-MRI, this is at the cost of 2% more biopsies and 1% more
overdetection of low-grade PCa. In order to implement this technique in nonexpert,
low-volume, lower-ﬁeld-strength scanners, further prospective studies have to be
performed.
Patient summary: We compared the value of three different magnetic resonance
imaging (MRI) protocols for the detection of prostate cancer in men with elevated
prostate-speciﬁc antigen levels. Our results show that, when used in expert centers,
shorter MRI protocols do not compromise the detection of harmful disease. This
increases MRI capacity at lower direct costs.
© 2019 The Authors. Published by Elsevier B.V. on behalf of European Association of
Urology. This is an open access article under the CC BY-NC-ND license (http://creati-
vecommons.org/licenses/by-nc-nd/4.0/).
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Multiparametric prostatemagnetic resonance imaging (mp-
MRI) with subsequent MR-directed biopsy of suspicious
lesions has been described to be a useful diagnostic method
to detect high-grade prostate cancer (PCa) in men with
elevated serumprostate-specific antigen (PSA) levels [1]. Re-
cent studies have shown thatmp-MRI can avoid unnecessary
prostate biopsy in biopsy-naïve men [2–5]. Furthermore, in
comparison with systematic transrectal ultrasound-guided
biopsies (SBs), detection rates of low-gradePCa are lowerand
those of high-grade PCa are similar or higher [2–5].
State-of-the-art full diagnostic mp-MRI of the prostate[1_TD$DIFF]
performed according to the Prostate Imaging Reporting and
Data System (PI-RADS) v2 guidelines, consists of T2-
weighted imaging (T2WI) in three orthogonal planes, and
diffusion-weighted imaging (DWI) and dynamic contrast-
enhanced (DCE) imaging after administration of intrave-
nous contrast material [6]. According to the PI-RADS v2
system, the role of DCE imaging is being reserved for the
clarification of equivocal abnormalities in the peripheral
zone [6]. The full PI-RADS-compliant protocol is, however,
time[4_TD$DIFF]-consuming and costly, and has implementation
challenges where MRI accessibility is limited. This may
restrict the routine use of MRI as a triage test in men with
elevated PSA.
Recent studies suggest that the use of DCE imaging and
T2WI in multiple planes does not improve the overall
accuracy of MRI [7,8]. Therefore, short, noncontrast bipara-
metric MRI (bp-MRI; ie, T2WI and DWI) has been suggested
to reduce examination time and cost, while retaining
sufficient diagnostic accuracy to “rule out” high-grade PCa
in biopsy-naïve men [9–13]. Furthermore, intravenous
access and potential gadolinium-based contrast agent-
related toxicities can be prevented [14,15]. Thus, we
conducted a multireader, prospective study to investigate
the diagnostic performance of currently used mp-MRI
versus noncontrast bp-MRI in three planes (bp-MRI) and in
one plane (“fast” bp-MRI) to detect high-grade PCa in
biopsy-naïve men.2. Patients and methods
2.1. Study population
This prospective, multicenter study was performed in accordance with
institutional review board requirements and was conducted from
February 2015 to February 2018. The full study protocol and results
have been described previously [2]. All included patients provided
written informed consent. Eligible men were aged 50–75 yr with a PSA
value of 3 ng/ml, with no history of prior biopsy. A total of 699 men
were referred by general practitioners and were enrolled by urologists
from one university center (Radboudumc, Nijmegen, n = 169), two
community hospitals (Ziekenhuis Groep Twente, n = 357, and Maasstad
Hospital, Rotterdam, n = 152), and one diagnostic center (Andros Men’s
Clinic, n = 21; Fig. 1).
2.2. MRI examination and image analysis
After written consent, patients underwent mp-MRI examinations on
3 TeslaMRI scanners (Magnetom Skyra; Siemens Healthineers, Erlangen,
Germany) with pelvic phased-array coils, according to PI-RADS v2
standards [6].
2.2.1. Multiparametric MRI examination
The mp-MRI protocol consisted of T2WI in three planes, DWI with
calculated high b-value images (b  1400 s/mm2[3_TD$DIFF]), and apparent diffu-
sion coefﬁcient (ADC) map and DCE imaging (Supplementary Table 1).
2.2.2. Biparametric MRI and “fast” bp-MRI evaluation
The bp-MRI protocol used the mp-MR images but without DCE imaging
(ﬁve image sets). The fast bp-MRI evaluation included only axial T2WI,
reconstructed axial ADC map, and high b-value images (three image
sets).
2.2.3. MRI assessment
Imageswere prospectively independently analyzed before biopsy by two
highly experienced radiologists: J.B. and M.v.d.L., with 25 and 5 yr of
experience with prostate MRI, respectively. Readers were informed
about clinical ﬁndings (ie, study participation, age, PSA level, and digital
rectal examination ﬁndings). First, the fast bp-MRI examination was
evaluated (Supplementary Fig. 1A–C; fast bp-MRI). The images were
assigned to PI-RADS v2 criteria for T2WI and DWI, and a ﬁnal PI-RADS
score was assessed and registered. Thereafter, the readers had the
[(Fig._1)TD$FIG]
Fig. 1 – Flow diagram of study design, participants, and MRI assessment. bp = biparametric; mp = multiparametric; MRI = magnetic resonance imaging;
PI-RADS = Prostate Imaging Reporting and Data System; PSA = prostate-specific antigen; TRUS= transrectal ultrasound.
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score for bp-MRI. For bp-MRI assessment, peripheral zone lesions scored
as PI-RADS 3 could not be “upgraded” to PI-RADS 4 because DCE imaging
was not available [6]. After the bp-MRI score was registered (Supple-
mentary Fig. 1A–E; bp-MRI), the DCE images became available, and the
ﬁnal PI-RADS score for the mp-MRI (Supplementary Fig. 1A–F; mp-MRI)
was assessed and documented [6]. In case of discordance for themp-MRI
readings between the two radiologists, consensus assessment was used
for biopsy decisions. Fast bp-MRI and bp-MRI discordances were
assessed 1 yr after study ﬁnalization, blinded to consensus mp-MRI
score and histopathology, without the possibility of post hoc alterations.
MRIﬁndingswere classiﬁed as suspicious in the presence of a PI-RADS 3–
5 lesion and nonsuspicious in case of PI-RADS categories 1–2.
2.3. Systematic and targeted biopsy
Menwith PI-RADS 3–5 lesions on themp-MRI examination underwent a
two- to four-core in-bore MR-guided biopsy (MRGB) of each suspicious
MRI lesion(s). Then, blinded to the MRI ﬁndings, a 12-core SB was
performed without additional cores targeting hypoechoic lesions, as
described previously [2].
2.4. Histopathological examination and high-grade PCa
definition
Biopsies were centrally reviewed by a uropathologist, blinded to the
initial histopathology and MRI results. In case of PCa, the International
Society of Urologic Pathology Grade (G) was assigned [16]. High-grade
PCa was deﬁned as any cancer core of G  2 (Gleason score 3 + 4).
Results from combined biopsies (MRGB and SB) were used as the
reference standard to assess outcomes.2.5. Outcome measurements
[5_TD$DIFF] he primary outcome was the diagnostic performance of each protocol
to detect high-grade PCa. Secondary outcomes included the number of
men avoiding biopsy for the three MRI protocols, low-grade PCa
detection rates, and acquisition times per protocol. Decision curve
analyses (DCAs) were performed for [2_TD$DIFF] different protocols. In addition, the
inter-reader agreement on the need for biopsy and “interprotocol”
agreement (between the three readings) [6_TD$DIFF]was analyzed. Direct costs per
protocol were assessed; costs for MR equipment, contrast consumables,
and labor according to the Dutch health care system guidelines were
calculated for the three MRI protocols [17,18].
2.6. Statistical analysis
Characteristics were described using medians and interquartile ranges
(IQRs) for continuous variables, and numbers with percentages for
categorical variables. In case of multiple lesions, the lesion with the
highest PI-RADS score was used as the index lesion. We tested
differences in sensitivity and speciﬁcity between the reference strategy
(mp-MRI) and the other strategies with McNemar’s x2 test. Differences
in negative (NPV) and positive (PPV) predictive values were tested using
the weighted generalized score method, as described by Kosinski
[19]. Associated 95% bias-corrected and accelerated bootstrapped
conﬁdence intervals (CIs) were obtained using 5000 replications. We
tested between protocol differences in PI-RADS 3 scores using a
Cochrane’s Q test followed by pairwise McNemar’s tests. Newcombe
CIs for differences of proportions with matched pairs were calculated
[20]. DCA for the different MRI protocols, including a conditional PSA
density (PSAd)-based biopsy strategy (0.15 ng/ml/ml) for equivocal (PI-
RADS 3) lesions, was performed, using threshold probabilities ranging
from5% to 20% [21–23]. Additional analyses for PSAd cutoffs of0.10 and
Table 2 – Sequence times per protocol (h:min:s)
Sequence mp-MRI bp-MRI “Fast” bp-MRI
T2WI localizers 0:00:51 0:00:51 0:00:26
T2WI localizer (sagittal) 0:00:07 0:00:07 0:00:00
T2WI sagittal 0:02:31 0:02:31 0:00:00
T2WI coronal 0:02:15 0:02:15 0:00:00
T2WI transversal 0:02:33 0:02:33 0:02:33
DWI 0:04:50 0:04:50 0:04:50
DCE imaging 0:02:50 0:00:00 0:00:00
Total sequence time 0:15:57 0:13:07 0:07:49
bp = biparametric; DCE = dynamic contrast enhanced; DWI = diffusion
weighted imaging; mp = multiparametric; MRI = magnetic resonance
imaging; T2WI = T2-weighted imaging.
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col agreement were calculated using Gwet’s agreement coefﬁcient (AC)
[24]. ACs were interpreted according to themethods described by Landis
and Koch (<0, poor; 0–0.20, slight; 0.21–0.40, fair; 0.41–0.60, moderate;
0.61–0.80, substantial; and 0.81–1.00, almost perfect) [25]. Statistical
analyses were performed using R (version 3.5.2; R Foundation for
Statistical Computing, Vienna, Austria).
3. Results
3.1. Patient characteristics and MRI results
A total of 699 men were prospectively enrolled; 73 men
were excluded for various reasons (Fig. 1). The final study
population consisted of 626menwith amedian age of 65 yr
(IQR 59–68). Median PSA level was 6.4 ng/ml (IQR 5.0–8.6).
Patients’ demographics, baseline characteristics, and MRI
findings are listed in Table 1. Acquisition times for each
protocol are provided in Table 2.
The mp-MRI and bp-MRI protocols were scored as
nonsuspicious (PI-RADS 1–2) in 309 (49%) men; for the fast
bp-MRI, the lesions were nonsuspicious in 295 (47%) men
(Supplementary Fig. 2). Equivocal lesions (PI-RADS 3) were
scored in 6.4% (40/626), 7.8% (49/626), and 11% (70/626) of
men for the mp-MRI, bp-MRI, and fast bp-MRI protocol,
respectively. Thus, comparedwithmp-MRI, bp-MRI and fastTable 1 – Patient characteristics and PI-RADS assessment per
protocol
Characteristics
Number of patients, n (%) 626 (100)
Median age at biopsy, yr (IQR) 65 (59–68)
1st-degree family history of PCa, n (%)
Positive 114 (23)
Unknown 1 (0.16)
DRE, n (%)
Abnormal 176 (28)
Unknown 5 (0.80)
Median PSA, ng/ml (IQR) 6.4 (5.0–8.6)
Median prostate volume, ml (IQR) 56 (41–77)
Median PSAd, ng/ml/ml (IQR) 0.11 (0.08–0.17)
PI-RADS v2 assessment, n (%)
“Fast” bp-MRI
1–2 295 (47)
3 70 (11)
4–5 261 (42)
bp-MRI
1–2 309 (49)
3 49 (7.8)
4–5 268 (43)
mp-MRI
1–2 309 (49)
3 40 (6.4)
4–5 277 (44)
Combined histology, n (%)
No cancer/benign 292 (47)
Low-grade PCa 144 (23)
High-grade PCa 190 (30)
bp = biparametric; DRE = digital rectal examination; IQR = interquartile
range; mp = multiparametric; MRI = magnetic resonance imaging;
PCa = prostate cancer; PSA = prostate-speciﬁc antigen; PSAd = prostate-
speciﬁc antigen density; PI-RADS = Prostate Imaging Reporting and Data
System.
Prostate volume was measured on MRI.bp-MRI had 1.4% (95% CI: 0.23–2.8; p = 0.03) and 4.8% (95%
CI: 2.9–6.9; p < 0.001) more PI-RADS 3 scores. This resulted
in 2.2% (14/626) less PI-RADS 1–2 scores for the fast bp-MRI
assessment, and 1.4% (9/626) and 2.6% (16/626) [7_TD$DIFF]fewer PI-
RADS 4 scores for the bp-MRI and fast bp-MRI assessments,
respectively.
3.1.1. Diagnostic performance
Using combined histopathology as the reference standard,
the sensitivity for high-grade PCa was 95% (180/190) for all
three protocols. Specificitywas lower (3.2% (95% CI 1.0–5.4);
p < 0.001) for the fast bp-MRI protocol (65% [285/436]) than
that for the bp-MRI and mp-MRI protocols (69% [299/436];
Table 3).
Compared with the NPV for high-grade PCa of the bp-
MRI andmp-MRI protocols (97% [299/317]), the NPV for the
fast bp-MRI (97% [285/295]) was lower (0.15% [95% CI 0.05–
0.31]; p < 0.001). The PPV for high-grade PCa was lower
(2.4% [95% CI 1.1–3.8]; p < 0.001) for the fast bp-MRI
protocol (54% [180/331]) compared with the bp-MRI and
mp-MRI protocols (57% [180/317]).
Owing to PI-RADS 3 instead of PI-RADS 1–2
diagnoses, fast bp-MRI would lead to additional
biopsies in 2.2% (14/626) of men. Biopsy of these men
would result in six additional low-grade PCa and eight
biopsies without PCa. Owing to focal-early enhancement
on mp-MRI, PI-RADS 3 lesions were “upgraded” to PI-
RADS 4 in nine men. There was, however, no change in
biopsy strategy for these men, as all PI-RADS 3 lesions
underwent MRGB. An overview of MRI and histopatholog-
ical results for each MRI protocol per 100 men is presented
in Fig. 2.
DCA showed that with biopsy thresholds ranging from
5% to 15%, restricting biopsies to men with suspicious bp-
MRI or mp-MRI, had the highest net benefit. At biopsy
thresholds ranging from 15% to 20%, a conditional approach
using fast bp-MRIwith PI-RADS 4–5 or PI-RADS 3with PSAd
0.15 ng/ml/ml showed the highest net benefit (Fig. 3). DCA
for other PSAd cutoffs (0.10 and 0.12 ng/ml/ml) per
protocol are described in Supplementary Fig. 3.
Direct cost reduction of the fast bp-MRI and bp-MRI
protocols are s143.35 (54%) and s98.95 (37%), respectively,
compared with the costs of themp-MRI protocol (s264.63),
[(Fig._2)TD$FIG]
Fig. 2 – MRI and histopathological results for each MRI protocol per 100 men. An overview of results for the three MRI protocols per 100 men, how
many biopsies were avoided, and how many low- and high-grade cancers were detected or missed. bp = biparametric; mp = multiparametric;
MRI = magnetic resonance imaging; PCa = prostate cancer.
Table 3 – Diagnostic performance per MRI protocol in the detection of high-grade PCa
Sensitivity Speciﬁcity NPV PPV LR LR+
% (95% CI) % (95% CI) % (95% CI) % (95% CI) (95% CI) (95% CI)
mp-MRI 95 (91–97) 69 (64–73) 97 (94–98) 57 (51–62) 0.077 (0.042–0.14) 3.0 (2.6–3.5)
bp-MRI 95 (91–97) 69 (64–73) 97 (94–98) 57 (51–62) 0.077 (0.042–0.14) 3.0 (2.6–3.5)
“Fast” bp-MRI 95 (91–97) 65 (61–70) 97 (94–98) 54 (49–60) 0.081 (0.044–0.15) 2.7 (2.4–3.1)
bp = biparametric; LR = negative likelihood ratio; LR+ = positive likelihood ratio; mp = multiparametric; MRI = magnetic resonance imaging; NPV = negative
predictive value; PPV = positive predictive value.
[(Fig._3)TD$FIG]
Fig. 3 – Decision curve analysis for the detection of high-grade PCa (PSAd 0.15 ng/ml/ml). Decision curve analysis using threshold probabilities
ranging from 5% to 20% for the three MRI protocols and additional PSAd-based (0.15 ng/ml/ml) strategies for PI-RADS 3 lesions. The protocol with the
highest net benefit regarding high-grade PCa at a specific threshold probability is clinically most useful. Of note, curves of bp-MRI and mp-MRI for PI-
RADS 3–5 are equal. DCA showed that with biopsy thresholds ranging from 5% to 15%, restricting biopsies to men with suspicious bp-MRI or mp-MRI
produced the highest net benefit. At biopsy thresholds ranging from 15% to 20%, a conditional approach using “fast” bp-MRI with PI-RADS 4–5 or PI-
RADS 3 with PSAd 0.15 ng/ml/ml produced the highest net benefit. Different PSAd cutoffs (0.10 and >0.12 ng/ml/ml) are shown in Supplementary Fig.
3. bp = biparametric; mp = multiparametric; DCA = decision curve analysis; MRI = magnetic resonance imaging; PCa = prostate cancer; PI-RADS = Prostate
Imaging Reporting and Data System; PSA = prostate-specific antigen; PSAd = PSA density.
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because of shorter scanning time costs (Table 4).3.1.2. Inter-reader agreement
The percent agreement between both readers regarding
whether to perform a biopsy (PI-RADS 1–2 vs PI-RADS 3–5)
was 90% (Gwet’s AC = 0.81; 95% CI: 0.76–0.85) for fast bp-
MRI and 93% (Gwet’s AC = 0.85; 95% CI: 0.81–0.89) for bp-
MRI and mp-MRI (Supplementary Table 2). The percentagreement between the three protocols per PI-RADS
category was 94% (Gwet’s AC = 0.92; 95% CI: 0.90–0.94).
4. Discussion
Comparedwith SB, prostate MRI has multiple advantages in
the detection and localization of high-grade PCa in biopsy-
naïve men [2–5]. However, limited capacity of scanners and
radiologists for prostate MRI and high costs restrict the use
Table 4 – Cost considerations
Direct MRI costs
mp-MRI bp-MRI “Fast” bp-MRI
Equipment costa s108 079.63 (2 scans/h) s72 413.35 (3 scans/h) s54 039.81 (4 scans/h)
Contrast consumablesa,b s23 076.45 s0 s0
Labor costa s34 502.31 s31 300 s21878.70
Total MRI costs s165 658.38 s103 713.34 s75 918.51
Cost per MRI s264.63 s165.68 s121.28
Cost reduction (%) – 37 54
bp = biparametric; mp = multiparametric; MRI = magnetic resonance imaging.
a Dutch cost guidelines and center’s reimbursement costs [23,24].
b Costs for gadolinium-based contrast agent, material, and MRI technologist.
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first prospective, multireader, blinded, direct comparison of
two different bp-MRI protocols with mp-MRI in biopsy-
naïve men.
The present study showed that MRI acquisition time can
substantially be reduced with faster, unenhanced bp-MRI
protocols[1_TD$DIFF] while maintaining the advantages of biopsy
avoidance without impairing the detection of high-grade
PCa. Both bp-MRI protocols had[8_TD$DIFF] a similar diagnostic
performance to that of mp-MRI with respect to “ruling
out” high-grade PCa. The use of a fast bp-MRI protocol did
not result in decreased detection of high-grade PCa. Even
though the NPV of fast bp-MRI was lower than that of bp-
MRI and mp-MRI, the difference in NPV between protocols
is clinically negligible (0.15% [95% CI 0.05–0.31]), and the
NPV of “fast” bp-MRI remains high (97%). This is in
agreement with two recent studies that prospectively
investigated bp-MRI protocols in biopsy-naïve men accord-
ing to PI-RADS v2 and reported NPVs of 93% and 96%
[9,11]. In contrast to our study, previous bp-MRI studies
were either single-reader evaluations, retrospectively con-
ducted or without adherence to the PI-RADS v2 recom-
mendations on image acquisition and readings [6,12].
The noncontrast bp-MRI examination time is approxi-
mately 13 min, a reduction of 20% compared with mp-MRI.
The fast bp-MRI protocol, without coronal and sagittal T2WI
planes, can further reduce the acquisition time to 8 min.
Therefore,[2_TD$DIFF] patient throughput can be doubled to four men
per hour. There are, however, diagnostic compromises of
the [9_TD$DIFF]“fast[10_TD$DIFF]” bp-MRI that have to be considered. It leads to 2.2%
(14/626) more biopsies and overdetection of 0.96% (6/626)
more low-grade PCa.
Although the exact costs of prostate MRI are highly
variable between different centers and countries, the
available literature estimates a price range between s230
and s855 for mp-MRI [26–29]. As clinical implementation
of fast bp-MRI could save approximately 50%, the total
direct costs perMRI examination becomes121 in our study.
We are aware that direct costs are part of the total costs, and
that a gain of direct costs may be reduced by extra costs due
to 2.2% more biopsies and detection of 0.96% more low-
grade PCa. Future analyses are needed to define the cost [4_TD$DIFF]-
effectiveness of these shorter protocols.
Omitting the coronal and sagittal T2WI planes in “fast”
monoplanar bp-MRI makes it more difficult to assignlesions to the zonal region (peripheral or transition zone), as
this is crucial to the determination of the final PI-RADS
score. This may explain why there is a 75% increase in PI-
RADS 3 “equivocal” cases with fast bp-MRI compared with
bp-MRI. This is an indicator of increased diagnostic
uncertainty resulting in more unnecessary biopsies. How-
ever, compared with Obmann et al. [9] (27%) and Boesen
et al. [11] (13%), the percentage of PI-RADS 3 cases in this
study for both bp-MRI protocols is rather low (7.8% and 11%).
This may be a result of the high-quality image acquisition
and expert reading of both bp-MRI studies. This emphasizes
the need for high-quality standards in image acquisition
and standardized reading. However, even though the
percentage of PI-RADS 3 cases of bp-MRI is rather low in
this study, it is still higher than that obtained with our mp-
MRI (6.4%). This potential diagnostic disadvantage can be
reduced by [11_TD$DIFF]adopting a different biopsy decision strategy:
our DCA shows that the highest net benefit can be achieved
by restricting biopsies tomenwith PI-RADS 3 lesions with a
PSAd of 0.15 ng/ml/ml.
There are several important features of bp-MRI that
facilitate clinical implementation of this technique: (1)
intravenous access is not needed, the procedure is
completely noninvasive through omitting the contrast
media administration, making it suitable also for patients
with impaired renal function; (2) patients are not exposed
to risks associated with contrast administration, including
allergic reactions, intracranial gadolinium deposits, and
nephrogenic systemic fibrosis [14,15]; and (3) patients are
required to lie motionless during the scan; therefore, a
substantial shortening of acquisition time will make the
MRI examination more tolerable for patients with claustro-
phobia and could potentially reduce motion artifacts [30]. A
potential disadvantage of implementing fast bp-MRI could
be high-grade PCa staging. Although in most cases, this is
possible by using high-resolution axial T2WI, a minority of
patients may have to undergo an additional MRI examina-
tion for better local staging. This is a short (10 min) MRI
examination, as it consists only of T2WI in two planes. These
planes can be added to the MRGB procedure.
Our study is not without limitations. First, the decision
that men need to have MRGB was based on the mp-MRI
assessment only. In other words, no MRGB histology was
retrieved from additional suspicious bp-MRI lesions, scored
as nonsuspicious in the mp-MRI assessment. This will,
E U RO P E AN URO LOGY 76 ( 2 019 ) 574 – 5 8 1580however, not negatively affect the detection of high-grade
PCa.
Second, our NPV was similar to that reported in other
studies comparing nonsuspicious MRI with SB [5,31]. How-
ever, the true diagnostic performance cannot be assessed as
we neither have the template mapping biopsy, as was
performed in the PROMIS study (NPV of 76% for PCa G 2)[1_TD$DIFF]
nor the prostatectomy specimen as the gold standard [4].
Third, the two readers involved in our study were expert
readers, with an annual caseload of approximately
1000 prostate MRI examinations per year. These readings
were performed only centrally, and peripheral readings
were not accounted for in this analysis. In addition, the
quality of the images obtained using a state-of-the-art 3 T
scanner was optimal. Therefore, our results are not directly
applicable to other lower-volume nonexpert centers. The
almost-perfect agreement between the protocols suggests
that PI-RADS v2 is effective as standardized reporting for
bp-MRI and mp-MRI. However, previous studies reported
moderate-to-high interobserver variability of PI-RADS v2
[32,33]. On the contrary, despite the difference in work
experience of both readers (5 vs 25 yr), there was an almost
perfect inter-reader agreement for all three MRI protocols.
For [12_TD$DIFF] the clinical implementation of any diagnostic technique,
the level of inter-reader variability plays a very important
role, reflecting the diagnostic robustness of the technique.
Future multicenter studies should investigate the gener-
alizability of inter-reader agreement for community cen-
ters.
Finally, the reading of the fast bp-MRI, bp-MRI, and mp-
MRI was performed in a set order rather than randomly,
which may have introduced a sequential reading bias.
However, prostate mp-MRI examinations are read similarly
in the “real life”: interpretation usually starts with [13_TD$DIFF] the
reading of the axial DWI and axial T2WI, then using
additional planes, and then finally evaluating the DCE
images.5. Conclusions
In this study, both bp-MRI protocols had an equal[2_TD$DIFF] detection
rate of high-grade PCa tomp-MRI. “Fast” bp-MRI can double
prostateMRI capacity at lower expenses. This is, however, at
the cost of 2% more biopsies and 1% more overdetection
of low-grade PCa. In order to implement this technique in
nonexpert, low-volume, lower-field-strength scanners,
further prospective studies have to be performed.
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